Vaxart (VXRT) Proxy filing summary

Executive summary

• Annual Meeting of Stockholders scheduled for July 16, 2026, with significant attention expected due to a contested board election.

• Leadership emphasizes commitment to advancing vaccine programs and transitioning to a sustainable commercial model.

• Communication highlights the importance of maintaining experienced leadership to continue progress.

• Forward-looking statements caution that actual results may differ due to various risk factors.

Voting matters and shareholder proposals

• A group of shareholders has nominated three director candidates to replace half of the current board.

• The board reviewed these nominees and determined they lack the necessary experience and expertise.

• Shareholders will be solicited to vote in support of the current board at the Annual Meeting.

Board of directors and corporate governance

• Current board consists of Steven Lo, Kevin P. Finney, Elaine J. Heron, W. Mark Watson, David Wheadon, and James B. Breitmeyer.

• Board and leadership team are focused on acting in the best interests of the company, shareholders, and patients.

• Board is actively communicating the qualifications of its directors to shareholders.